AFP and neoplasm: The poorer prognosis in patients with AFP ≥ 200 ng/ml following TACE may relate to the greater tumour burden at baseline including tumour size (p = 0.002) and macrovascular invasion (p = 0.035) along with greater inflammatory response to treatment with higher serum ALT (p = 0.03) and neutrophil count (p = 0.001).